Educational content only. Not medical advice. Consult a qualified physician.
Cerebrolysin peptide
CognitiveApproved in over 40 countries for neurological indications. Not FDA-approved in the United States. Has extensive clinical trial data, including randomized controlled trials.

Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue through enzymatic proteolysis. Developed by EVER Neuro Pharma in Austria, it has been approved in over 40 countries for stroke, traumatic brain injury, and dementia. It acts as a multimodal neurotrophic agent mimicking the effects of natural neurotrophic factors.
Reported Benefits

Potential Benefits

  • Approved in multiple countries for acute ischemic stroke and traumatic brain injury
  • Clinical trials suggest potential benefits for vascular dementia and Alzheimer's disease
  • Research indicates neurotrophic effects similar to BDNF, NGF, and CNTF
  • May support neuroplasticity and synaptic remodeling based on clinical data
  • Meta-analyses of stroke trials suggest improvements in neurological outcomes
Research Dosing

Recommended Starting Dose

5-10 mL intravenously per day for cognitive applications (clinical doses range from 10-30 mL for acute stroke)

Based on published research protocols. Not a prescription.

Dosing Protocol

In clinical settings, Cerebrolysin is administered IV at 10-30 mL daily for stroke (typically diluted in saline over 15-60 minutes) for 10-21 days. For cognitive support, lower doses of 5-10 mL IV or IM daily for 10-20 day cycles, repeated every 1-3 months, are used. Must be administered by healthcare professionals.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

In stroke trials, neurological improvements were assessed at 30 and 90 days. For cognitive applications, benefits may be measured over weeks to months of cyclical treatment.

Regulatory

Research Status

Approved in over 40 countries for neurological indications. Not FDA-approved in the United States. Has extensive clinical trial data, including randomized controlled trials.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • Must be administered intravenously or intramuscularly (not available orally)
  • Headache
  • Dizziness
  • Injection site reactions
  • Agitation in some patients
  • Rare allergic reactions
  • Fever in some cases
  • Derived from animal tissue, which may concern some individuals
Related Research

More in Cognitive

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.